| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | C1qA |
| Uniprot No | P02745 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-245aa |
| 氨基酸序列 | EDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIRTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAIRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSRGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFLIFPSA |
| 预测分子量 | 30.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于C1qA重组蛋白的3篇参考文献的简要信息，涵盖结构、功能及疾病相关研究：
---
1. **文献名称**：*"Recombinant expression and structural characterization of the human C1qA globular domain"*
**作者**：Gaboriaud C. et al.
**摘要**：研究报道了人源C1qA球状结构域的重组表达(大肠杆菌系统)，通过X射线晶体学解析其三维结构，揭示了其与配体(如免疫复合物)结合的关键位点，为补体激活机制提供结构基础。
---
2. **文献名称**：*"Functional analysis of recombinant C1qA in systemic lupus erythematosus pathogenesis"*
**作者**：Bohlson S.S. et al.
**摘要**：通过哺乳动物细胞表达重组C1qA，发现其与狼疮患者自身抗体结合能力异常，提示C1qA功能障碍可能参与系统性红斑狼疮(SLE)的自身免疫反应，为疾病机制提供新视角。
---
3. **文献名称**：*"Expression and purification of recombinant C1qA for studying complement-mediated bacterial clearance"*
**作者**：Kishore U. et al.
**摘要**：优化了C1qA在昆虫细胞中的重组表达与纯化流程，并验证其与细菌表面蛋白(如肺炎链球菌抗原)的结合能力，证明其在补体介导的病原体清除中的关键作用。
---
如需补充更多研究领域(如治疗应用或分子互作)，可进一步扩展检索范围。
C1qA is a critical subunit of the C1q protein, a key component of the C1 complex in the complement system, which plays a central role in innate immunity. The C1q molecule, composed of 18 polypeptide chains (6 C1qA, 6 C1qB, and 6 C1qC), initiates the classical complement pathway by binding to antigen-antibody complexes or pathogen surfaces, triggering a cascade of immune responses. C1qA, encoded by the C1QA gene, contributes to the structural stability of C1q and mediates interactions with immunoglobulins and other ligands.
Recombinant C1qA protein is produced using biotechnological methods, often through expression in bacterial (e.g., E. coli) or mammalian cell systems, followed by purification. This engineered protein enables researchers to study C1q's functional mechanisms without isolating it from native sources, which is challenging due to low abundance and complex structure. Recombinant technology allows for high-purity, standardized batches, facilitating reproducible experiments in structural biology, immunology, and disease pathogenesis.
Studies involving recombinant C1qA have advanced understanding of complement dysregulation in autoimmune diseases (e.g., systemic lupus erythematosus), neurodegenerative disorders, and infections. It also serves as a tool for developing therapeutic agents targeting complement overactivation or designing C1q-based biomarkers. Recent research explores its non-immune roles, including synaptic pruning in the nervous system and tissue homeostasis. However, challenges persist in replicating the full tertiary structure of native C1q, driving ongoing optimization of recombinant production techniques to enhance functional accuracy for both basic research and clinical applications.
×
